Adjuvant therapy with essential fatty acids (EFAs) for primary liver tumors: some hypotheses.
Hepatocarcinoma is responsible for approximately 1 million deaths annually. It is usually discovered at an advanced stage and, if inoperable, has a poor prognosis. New therapies combining chemotherapy, hyperthermia, radiotherapy and immunomodulators have been recently attempted with various levels of success. Once the tumor is detected at an early stage, some possibilities of cure seem to emerge either by intratumoral percutaneous injection (PEI) of alcohol or by chemoembolization and interstitial hyperthermia. When the tumor volume is more than 5 cm, these therapies are less successful and radiotherapy can be used. All the techniques described have some limits; PEI, for instance, does not achieve a complete eradication of lesions > 3 cm and a non-homogenous alcohol distribution within the tumor leads to areas of necrosis. Radiotherapy, even if effective, is limited by dose-related radiation hepatitis. Another important limiting factor is the incomplete response to therapy and tumor recurrence. Essential fatty acids, especially gamma linolenic acid (GLA) and eicosapentaenoic acid (EPA) are discussed here for their ability to control primary tumor proliferation and increase response to chemotherapy, radiotherapy and hyperthermic treatment, thanks to their effects on cellular membranes (increased lipoperoxidation and modification of tumor stroma).
Baronzio
G F
GF
Association P Merlo, Turbigo (Mi), Italy.
Solbiati
L
L
Ierace
T
T
Barzaghi
F
F
Suter
F
F
Airoldi
M
M
Belloni
G
G
Ravagnani
F
F
Notti
P
P
Gramaglia
A
A
D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000503:physiopathology / Q000628:therapy*; D002462:Cell Membrane / Q000502:physiology; D005228:Fatty Acids, Essential / Q000502:physiology / Q000627:therapeutic use*; D006801:Humans; D015227:Lipid Peroxidation; D008113:Liver Neoplasms / Q000503:physiopathology / Q000628:therapy*; D008954:Models, Biological
D005228:Fatty Acids, Essential